Cardiol Therapeutics files $150 million shelf prospectus

TORONTO - Cardiol Therapeutics Inc., a publicly traded company, has filed a preliminary short form base shelf prospectus with Canadian securities regulators and a corresponding registration statement with the U.S. Securities and Exchange Commission, according to a press release. The filing does not involve the sale of any securities, but rather enables the company to offer and sell various types of securities in the future, potentially raising up to $150 million within a 25-month timeframe.

The prospectus includes additional details regarding the company's research and development programs, general and administrative expenses, net loss, cash flows, and cash position. Cardiol Therapeutics is a company focused on developing treatments for heart disease, with its Phase III MAVERIC trial currently evaluating an anti-inflammatory and anti-fibrotic drug for treating recurrent pericarditis.